Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase I safety study of olprinone for low central venous pressure management during open hepatectomy
jRCTs041230111Phase 1Completed
- Start
- Jan 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of olprinone in hepatocellular carcinoma (HCC), intrahepatic cholangiocarcinoma (ICC), liver cancer and 1 more. Primary endpoints: Dose-limiting toxicity during surgery, Dose-limiting toxicity from end of surgery to 24 hours post-operation and 1 more. Started Jan 2024; status: completed.
02
Drugs
olprinone
03
Conditions
hepatocellular carcinoma (HCC)intrahepatic cholangiocarcinoma (ICC)liver cancerhilar cholangiocarcinoma (HC)
Beyond the preview
Go deeper on jRCTs041230111.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCTs041230111.